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Abstract Improved laboratory standards and better culture media have made extended culture to blastocyst stage a reality to iden-
tify embryos with maximum implantation potential. The strategy of extended culture has become more popular across the world at
a time when regulatory bodies have emphasized the need to increase the uptake of elective single embryo transfer, minimize com-
plications associated with multiple births and aim for a healthy singleton live-birth as the preferred outcome in IVF. New data on
perinatal outcomes suggest that pregnancies after embryo transfer at blastocyst stage are associated with a higher risk of preterm
delivery, large for gestational age babies, monozygotic twins and altered sex ratio compared with those following embryo transfers
at cleavage stage. In addition, concerns have been raised of increased congenital anomalies and epigenetic modiﬁcations with embryo
transfer at blastocyst stage. Twenty-four years on from the ﬁrst embryo transfer at blastocyst stage, we examine the reasons for
extended embryo culture, evaluate the risks and beneﬁts of this strategy and suggest the need to reconsider this policy in the in-
terests of fetal safety.
© 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
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Introduction
Advances in our knowledge of in-vitro culture conditions have
led to the development of stage-speciﬁc or sequential media
(Gardner et al., 1998), making it possible to conduct rou-
tinely extended culture of embryos to the blastocyst stage.
The ﬁrst reports of pregnancy and live birth from an embryo
transferred at blastocyst stage (day 5–6 after egg collec-
tion) were published in 1985 (Cohen et al., 1985) and 1991
(Bolton et al., 1991), respectively. Since then, a constant in-
crease in proportion of embryo transfers at blastocyst stage
has been reported (from 1% in 2000 to 34% in 2012 in UK
(http://www.hfea.gov.uk/104.html).
In this paper, we examine the reasons for extended embryo
culture, evaluate the risks and beneﬁts of this strategy and
consider whether a policy of embryo transfer at blastocyst
stage is still justiﬁed.
Reasons for choosing extended culture
Extended culture has been considered to be a better option
than cleavage stage embryo transfer for a number of reasons.
Physiological synchronization
Transfer of the embryo to the uterine cavity after 5 days of
insemination or injection is thought to provide better embryo–
endometrium synchrony, and therefore higher chances of im-
plantation as it mimics more closely the sequence of events
in natural conception. Unlike the situation in a natural
cycle, however, ovarian stimulation during IVF leads to
supraphysiological levels of oestrogen and progesterone, which
enhances the endometrial development, i.e. the endome-
trial milieu at day 3 after egg collection (in a stimulated
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environment) could be similar to the endometrial milieu on
day 5 (after ovulation) in a natural cycle owing to the effect
of ovarian stimulation (Kolibianakis et al., 2002).
Embryo selection
Activation of the embryonic genome occurs at the eight-cell
stage (day 3). In the absence of activation, the embryo is un-
likely to survive or implant. An obvious way to ensure this is
to extend the duration of culture to blastocyst stage – a
process that allows identiﬁcation of embryos that have
managed to activate their embryonic genome.
If embryo development between days 3 and 5 and 6 were
solely based on inherent survival potential and embryonic ac-
tivation, this would have been the ideal way to screen out
poor-quality embryos. This is not necessarily the case, as in-
vitro survival does not equate to in-vivo survival, which
depends on the culture system used, e.g. medium, number
and types of incubators and oxygen tension. By committing
to embryo transfer at blastocyst stage, there is a risk of losing
some embryos, which might not survive the challenge of ex-
tended culture but might have, if transferred to the uterus,
survived in vivo, implanted and resulted in a pregnancy.
Blastocyst transfer improves the odds of transferring a
viable embryo (Harton et al., 2013) but does not guarantee
euploidy. Morphological scoring, either at blastocyst or cleav-
age stage, is not an accurate way of identifying chromo-
somal abnormalities, and recent studies have shown that
chromosomally abnormal embryos can become blastocysts
(Fragouli et al., 2014).
Improved live birth rates
A meta-analysis of 12 randomized controlled trials (RCT)
showed a signiﬁcant increase in live birth rate per started
treatment when embryo transfer was carried out at blasto-
cyst stage compared with cleavage stage (odds ratio [OR] 1.40,
95% conﬁdence interval [CI] 1.13 to 1.74). Meta-analysis of
four RCT showed that cumulative pregnancy rates, i.e. number
of births from one egg collection, are signiﬁcantly higher (OR
1.58, 95% CI 1.11 to 2.25) in embryo transfers carried out at
cleavage stage compared with those at blastocyst stage
(Glujovsky et al., 2012). The possible reason for decreased
cumulative live birth rate with extended culture is that a
number of embryos that do not reach blastocyst stage are dis-
carded and not eligible for transfer. If these are frozen at
cleavage stage and transferred after successful thawing, preg-
nancies can be achieved. This means that minimizing embryo
wastage in in-vitro culture could lead to the possibility of more
pregnancies and therefore higher cumulative live birth rate
even in those with good prognosis.
One can argue that this could be attributed to different
media and culture conditions, as optimal culture conditions
should ensure that the most embryos survive culture between
days 3 and day 5. The data presented above, however, are
from ameta-analysis of four RCT reporting on cumulative preg-
nancy rates. None of the trials compared the cost of extend-
ing the culture or extra freezing on day 3.
Comprehensive chromosome screening
Other reasons to extend embryo culture to day 5 include a
strategy of comprehensive chromosome screening after day
5 biopsy. Embryos are frozen in these situations with a view
to deferred embryo transfer, as it is difﬁcult for biopsy results
to be returned in time for embryo transfer. Increasing evi-
dence from RCT show that comprehensive chromosome screen-
ing at the blastocyst stage improves implantation and
pregnancy rates (Forman et al., 2013; Scott et al., 2013; Yang
et al., 2012). These, however, are yet to become incorpo-
rated into routine clinical practice in most centres and will
not be discussed further in this commentary.
Deferred embryo transfer
Electively freezing all embryos with routine use of frozen and
thawed embryo transfer has been much debated (Maheshwari
and Bhattacharya, 2013). This is being evaluated in a number
of ongoing clinical trials, and has yet to ﬁnd universal accep-
tance. In this commentary, we therefore focus on the pros
and cons of day 5 versus day 3 embryos in conventional IVF
where fresh embryo transfer is the norm and the rationale
for extended culture is to select the best embryo.
Obstetrics and perinatal outcome of
pregnancies
As good-quality embryos from women with the best progno-
sis tend to be selected for extended culture, one would expect
perinatal outcomes to be better in pregnancies as a result of
blastocyst transfer. This does not, however, seem to be the
case.
Preterm delivery
Two separate meta-analyses have conﬁrmed that IVF preg-
nancies resulting from embryo transfer at blastocyst stage were
associated with a higher relative risk (95% CI) of preterm (<37
weeks) (1.27 [1.22 to 1.31]) and very preterm (<32 weeks)
delivery (1.22 [1.10 to 1.35]) compared with with those re-
sulting from the transfer of cleavage stage embryos (Dar et al.,
2014; Maheshwari and Bhattacharya, 2013; Maheshwari et al.,
2013). Both meta-analyses were based on published obser-
vational data, hence were unable to adjust for confound-
ers, although, in individual studies, adjusted odds ratio was
used. Conclusive evidence for increase in preterm delivery
can only be provided by adequately powered RCT.
Risk of monozygous twins
Existing data suggest an increased chance of monozygotic twins
(Luke et al., 2014) associated with blastocyst transfer with
a pooled odds ratio of 3.04 (95% CI 1.54 to 6.01) (Chang et al.,
2009) compared with embryo transfer at cleavage stage. The
exact reason for this increase is not known, but alteration in
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the zona pellucida induced by extended culture is thought to
be responsible.
Large for gestational age babies
Data from animal as well as human studies have suggested
that extended culture leads to large for gestation offspring
(Zhu et al., 2014). The authors of this study admit that a key
limitation of their study was that extended culture was mainly
offered to poor-prognosis patients (unsuccessful IVF cycles or
with uterine malformations), resulting in potential selec-
tion bias. Even gender-adjusted birth weight (Z scores) are
higher for newborns after embryo transfer at blastocyst stage
when compared with those after day 2 or 3 embryo trans-
fers (Mäkinen et al., 2013), albeit only a small number had
embryo transfer at blastocyst stage.
An increased proportion of large for gestational age babies
may be the reason that meta-analysis (Maheshwari and
Bhattacharya, 2013; Maheshwari et al., 2013) suggests a de-
creased risk of intrauterine growth retardation with blasto-
cyst stage embryo transfer compared with those at cleavage
stage. It could be argued that the type of culture media used
in extended culture could be responsible for large for gesta-
tional age babies; however, a recent study seems to refute
this (De Vos et al., 2015).
Congenital anomalies
A recent meta-analysis (Dar et al., 2014) reported that the
odds of congenital anomalies were signiﬁcantly higher for
babies born after embryo transfer at blastocyst stage com-
pared with those born after embryo transfer at cleavage stage
(1.29, 95% CI 1.03 to 1.62).
Altered male: female ratio
Several reports have suggested that blastocyst transfer leads
to an altered sex ratio with a male–female ratio of 1.29 (95%
CI 1.10 to 1.51) (Chang et al., 2009).
Reasons for adverse perinatal outcomes after
extended culture
Although extended culture is usually offered to good-prognosis
women in whom better perinatal outcomes are expected, the
results of some of the existing studies seem to suggest the
opposite. A possible explanation could be that extended
culture may trigger genetic and epigenetic changes in
trophodermal cells that can lead to abnormal placentation
and implantation, and hence increased risk of preterm de-
livery. Results from animal studies support this hypothesis
(Rizos et al., 2002).
Why do we still continue with extended
culture?
Despite the concerns highlighted above (Figure 1), extend-
ing culture to blastocyst stage seems to be the preferred strat-
egy among many IVF clinics, and its popularity has grown
exponentially in recent years. The key drivers for this ap-
proach are the importance clinics, commissioners and pa-
tients attach to the realization of short-term goals (higher
pregnancy rates per embryo transfer episode) and their po-
sition in national league tables based on success rates. This
is mainly due to the fact that single embryo transfer at blas-
tocyst stage leads to a signiﬁcantly higher pregnancy rate per
embryo transfer compared with those at cleavage stage.
Factors favouring 
blastocyst stage 
embryo transfer 
Factors favouring 
cleavage stage 
embryo transfer 
Figure 1 Balance between blastocyst and cleavage stage embryo transfer.
144 A Maheshwari et al.
Do we need to change our focus?
As clinicians, our focus has shifted from live birth as the sole
measure of treatment success to outcomes which reﬂect feto–
maternal safety, especially when evidence is emerging that
birth outcomes can be predictive of diseases in later life. It
is increasingly becoming clear that the goal of assisted re-
production should be to achieve a healthy live baby with the
potential to develop into a healthy adult.
Pregnancies achieved through IVF, even in singletons, are
associated with higher rates of preterm deliveries com-
pared with those conceived spontaneously. This risk is further
increased in pregnancies after embryo transfer at blasto-
cyst stage compared with embryo transfer at cleavage stage.
If one adds the risks associated with monozygotic twins, large
for gestational age and congenital anomalies there are further
concerns about safety of future generations.
Moreover, it is clear that, although we go to extreme
lengths to select the ‘best’ embryo, current tests of embryo
quality lack precision, and pregnancies can arise from non-
top quality embryos as well as those which never make it to
blastocyst stage. Extended culture in women with very few
embryos incurs the risk of either having no embryos for trans-
fer in a fresh cycle or cryopreservation for future use. Hence
we do need to consider alternative strategies.
What needs to be done to change the status
quo?
In order for change to occur, a number of processes will need
to be instituted.
Reporting of IVF success rates will need to change
As scientists, healthcare providers and public health profes-
sionals, we have an obligation to ensure that the data we
present on efﬁcacy is consistent with our overarching objec-
tives of promoting safe motherhood and the birth of healthy
children. It is only when safety is a prominent part of report-
ing that the clinics and clinicians will accept strategies, which
may not give instant results but are better for the long term.
Although the currently favoured outcome ‘Live birth per cycle’
is understood and accepted by stakeholders, it is outdated
and needs updating to reﬂect both the risks as well as the ef-
fectiveness of the treatment. The most important param-
eter for the couple is the ultimate cumulative healthy baby
rate per started cycle. Success rates based on cumulative
healthy baby rates will provide patients with a direct measure
that will better enable them to make informed decisions about
whether and how to undergo IVF treatment in a way that maxi-
mizes their chance for a healthy infant from one episode of
egg collection.
Change the perceptions of stakeholders
No data have been published on patients’ preferences on
embryo transfer at cleavage stage or blastocyst stage. Studies
are urgently needed to establish which reproductive out-
comes couples value, i.e. instant gratiﬁcation (higher live birth
per fresh embryo transfer episode) versus delayed realisation
of goals (higher cumulative live birth, i.e. all live births from
one egg collection episode, with fewer complications for
mother and baby).
A planned, multifaceted strategy to educate all relevant
stakeholdersis is needed to change the prevailing culture. Al-
though this may seem to be an impossible task, there are prec-
edents in this ﬁeld. For example, a similar situation was faced
when elective single embryo transfer was promoted over
double embryo transfer. Although initial progress was slow,
most clinics, healthcare funders, as well as patients, under-
stand the importance of achieving one baby at a time in the
interest of feto–maternal safety, even though this results in
a delay in having a second baby.
Change the way IVF treatment is funded
No data are available to support the choice between ex-
tended culture as a cost-effective option from a societal per-
spective compared with embryo transfer at cleavage stage.
In most clincs, the charge for IVF treatment only includes fresh
embryo transfer. If couples were to freeze spare embryos and
use them later they need to pay more. This way of costing
IVF encourages couples to focus on short-term gains. Guid-
ance in UK by National Institute of Health and Care Excel-
lence in 2013 (CG 156, NICE, UK) recommends that fresh and
all associated frozen and thawed transfer cycles should be
counted as part of one IVF cycle but, even in the UK, this strat-
egy has only been followed by a few clinics for publicly funded
treatments.
Follow-up studies
The oldest baby born after embryo transfer at blastocyst stage
is just under 20 years old. Although, adverse perinatal out-
comes have been reported, long-term outcomes are still to
be revealed. More follow-up studies on long-term health of
children born by embryo transfer at both cleavage and blas-
tocyst stages are needed throughout the world to deter-
mine the ﬁnal recommendations for clinical practice. Such
collaborative studies should be encouraged now that most
countries have registries for those having treatment using as-
sisted reproduction techniques.
Better selection on day 3
Investment should be made on evaluating new technology such
as time lapse, to select the best embryo on day 3 to give
maximum number of pregnancies per treatment by increas-
ing the cumulative pregnancy rate and reducing pre-term
delivery.
Conclusion
Embryo transfer at blastocyst stage has become the strat-
egy of choice for most clinics worldwide, with the aim of
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achieving a healthy singleton live-birth and so minimizing the
number of multiple births and their associated complica-
tions, while still maintaining pregnancy rates per transfer. This
has been achieved by carrying out a single blastocyst trans-
fer instead of single embryo transfer on day 3. Although this
leads to higher live birth rates per embryo transfer episode,
it ultimately results in lower cumulative live birth rates per
couple, higher risk of preterm birth, large for gestational age,
monozygotic twins and congenital anomalies compared with
embryo transfer at cleavage stage.
The evidence presented in this commentary clearly high-
lights reasons for concern, with the possibility of epigenetic
changes resulting from extended culture and potential in-
creased risks to fetal health. The available data at present
are weak and do not justify stopping extended culture but,
in the interest of long-term outcomes, it is perhaps time to
rethink the current policy of blastocyst transfer. Larger RCT
of day 3 versus day 5 embryo transfer, involving highly ex-
perienced laboratories and including longer term follow-up
data on offspring outcome are necessary to provide conclu-
sive evidence for or against blastocyst transfer.
The main drivers for extended culture include clinics’ keen-
ness to secure a favourable position in national league tables
and an intuitive desire to maximise short term reproductive
success. It is therefore of utmost importance that league tables
reﬂect safety as well as efﬁcacy. In addition, appropriate strat-
egies are needed to inform all stakeholders about the value
of appreciating long term reproductive outcomes. Once all
the information about the short- and long-term implications
is available, it is only then that information should be dis-
cussed with a couple and a decision should be made which
is right for them rather than solely promoting the policy of
embryo transfer at blastocyst stage.
As providers of IVF treatment, we have an obligation to
minimize complications associated with IVF and safeguard the
long-term health of future generations.
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